- Joined
- Sep 30, 2015
- Messages
- 31,224
- Reaction score
- 46,132
- Points
- 113
Will "Marburg" be the next pandemic?
They already have a ricin based vax prepared for it. Ricin. Yeah, that poison stuff that nutjobs send in the mail. Aptly named "rivax".
Explanation vid:
https://t.me/toresaysPlus/12004
Rivax site:
https://www.soligenix.com/pipeline-programs/rivax-to-prevent-ricin-poisoning/
"RiVax® has Fast Track designation for the prevention of ricin intoxication by the US FDA.
RiVax® has been granted Orphan Drug designation for the prevention of ricin intoxication by the US FDA and by the European Medicines Agency (EMA).
As a new chemical entity, an FDA approved RiVax® vaccine has the potential to qualify for a biodefense Priority Review Voucher (PRV), which allows the holder to qualify for accelerated review by the FDA, potentially enabling a blockbuster drug to come on the market sooner and have a longer lifetime before patent expiry. PRVs are transferable and can be sold, with sale values in excess of $100 million recorded to date.
Soligenix has a strong worldwide intellectual property position on the composition of matter of RiVax®, the unique thermostabilized formulation for RiVax® and the combination of RiVax® with other subunit vaccines in a single vaccine.
Orphan Drug designation also confers 7 years market exclusivity in the US and 10 years in Europe, if approved."
They already have a ricin based vax prepared for it. Ricin. Yeah, that poison stuff that nutjobs send in the mail. Aptly named "rivax".
Explanation vid:
https://t.me/toresaysPlus/12004
Rivax site:
https://www.soligenix.com/pipeline-programs/rivax-to-prevent-ricin-poisoning/
"RiVax® has Fast Track designation for the prevention of ricin intoxication by the US FDA.
RiVax® has been granted Orphan Drug designation for the prevention of ricin intoxication by the US FDA and by the European Medicines Agency (EMA).
As a new chemical entity, an FDA approved RiVax® vaccine has the potential to qualify for a biodefense Priority Review Voucher (PRV), which allows the holder to qualify for accelerated review by the FDA, potentially enabling a blockbuster drug to come on the market sooner and have a longer lifetime before patent expiry. PRVs are transferable and can be sold, with sale values in excess of $100 million recorded to date.
Soligenix has a strong worldwide intellectual property position on the composition of matter of RiVax®, the unique thermostabilized formulation for RiVax® and the combination of RiVax® with other subunit vaccines in a single vaccine.
Orphan Drug designation also confers 7 years market exclusivity in the US and 10 years in Europe, if approved."